PA8578001A1 - Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas - Google Patents

Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas

Info

Publication number
PA8578001A1
PA8578001A1 PA20038578001A PA8578001A PA8578001A1 PA 8578001 A1 PA8578001 A1 PA 8578001A1 PA 20038578001 A PA20038578001 A PA 20038578001A PA 8578001 A PA8578001 A PA 8578001A PA 8578001 A1 PA8578001 A1 PA 8578001A1
Authority
PA
Panama
Prior art keywords
antineoplasic
erb
therapies
therapeutic combinations
quinasa
Prior art date
Application number
PA20038578001A
Other languages
English (en)
Inventor
William Leon Elliott
David William Fry
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8578001A1 publication Critical patent/PA8578001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA ADMINISTRACION DE UN INHIBIDOR IRREVERSIBLE DE TIROSINA QUINASA TAL COMO C1-1033 EN COMBINACION CON UNO O MAS AGENTES ANTINEOPLASICOS, O RADIACION IONIZANTE, ES SINERGICA PARA TRATAR EL CANCER.
PA20038578001A 2002-08-07 2003-07-22 Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas PA8578001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
PA8578001A1 true PA8578001A1 (es) 2004-05-07

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038578001A PA8578001A1 (es) 2002-08-07 2003-07-22 Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas

Country Status (17)

Country Link
US (2) US20040067942A1 (es)
EP (1) EP1549320A1 (es)
JP (1) JP2005538129A (es)
CN (1) CN1674908A (es)
AR (1) AR040792A1 (es)
AU (1) AU2003249450A1 (es)
BR (1) BR0313470A (es)
CA (1) CA2494270A1 (es)
IL (1) IL166423A0 (es)
MX (1) MXPA05001430A (es)
NO (1) NO20051170L (es)
PA (1) PA8578001A1 (es)
PE (1) PE20040990A1 (es)
PL (1) PL375414A1 (es)
RU (1) RU2005102836A (es)
TW (1) TW200404532A (es)
WO (1) WO2004014386A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) * 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
KR20070011457A (ko) 2004-04-09 2007-01-24 추가이 세이야쿠 가부시키가이샤 신규 수용성 프로드럭
MXPA06012756A (es) * 2004-05-06 2007-01-16 Warner Lambert Co 4-fenilamino-quinazolin-6-il-amidas.
CA2567852A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
RU2006146625A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr)
CN1960732A (zh) * 2004-06-03 2007-05-09 霍夫曼-拉罗奇有限公司 用吉西他滨和egfr－抑制剂治疗
JP2008501708A (ja) * 2004-06-04 2008-01-24 スミスクライン ビーチャム （コーク） リミテッド がんの治療方法
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
KR20140050609A (ko) * 2011-05-06 2014-04-29 메리맥 파마슈티컬즈, 인크. 항-ＥｒｂＢ3 제제들을 포함하는 조합 요법들에서 독성의 약물-약물 상호작용들을 예방하는 방법들
US20210275518A1 (en) * 2020-03-06 2021-09-09 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
SK9072003A3 (en) * 2001-01-09 2003-11-04 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors

Also Published As

Publication number Publication date
EP1549320A1 (en) 2005-07-06
RU2005102836A (ru) 2005-08-10
PE20040990A1 (es) 2004-12-27
PL375414A1 (en) 2005-11-28
US20040067942A1 (en) 2004-04-08
IL166423A0 (en) 2006-01-15
NO20051170L (no) 2005-05-06
WO2004014386A1 (en) 2004-02-19
US20060293323A1 (en) 2006-12-28
JP2005538129A (ja) 2005-12-15
CN1674908A (zh) 2005-09-28
CA2494270A1 (en) 2004-02-19
AR040792A1 (es) 2005-04-20
AU2003249450A1 (en) 2004-02-25
TW200404532A (en) 2004-04-01
MXPA05001430A (es) 2005-06-06
BR0313470A (pt) 2005-06-21

Similar Documents

Publication Publication Date Title
PA8578001A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
PH12020550936A1 (en) Combination drug including tlr7 agonist
NZ758548A (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
UY31017A1 (es) Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
EA200801671A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
PL1682126T3 (pl) Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EP1631267A4 (en) METHOD FOR THE TREATMENT OF DISORDERS WITH HSP90-INHIBITING AGENTS COMBINED WITH ANTIMETABOLITES
MX2021006408A (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de da?os y reparaciones del adn.
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
MXPA05013478A (es) Combinaciones terapeuticas.
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4